The development of controlled-release dosage forms (CRDFs) is highly desirable both from a convenience and compliance perspective. Furthermore, these formulations release drugs at a prescribed rate, leading to relatively constant blood drug concentrations or to pulse dosing. Another benefit is the ability to administer medications in infrequent regimens. For example, antimicrobial agents generally require very frequent administration regimens. In recent years, the pharmaceutical industry has realized the potential of this treatment modality and efforts have been made to develop a variety of CRDFs exclusively for veterinary use. While there are a number of controlled-release products available for veterinary applications, only a limited number of therapeutic niches (such as the application of antiparasitic drugs in cattle) are associated with products that have been developed as oral controlled-release products. In addition to reviewing potential new therapeutic areas where oral controlled-release products can be applied in veterinary medicine, this article reviews differences in the gastrointestinal tracts of various species and the significance of the dissimilarity in the development of CRDFs. Technological aspects involved in veterinary CRDFs are also assessed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.v23.i3.10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How Will Nanomedicine Revolutionize Future Dentistry and Periodontal Therapy?
Int J Mol Sci
January 2025
Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio", via dei Vestini 31, 66013 Chieti, Italy.
Periodontitis is a prevalent inflammatory disease affecting the supporting structures of the teeth, leading to gum recession, tooth loss, and systemic health complications. Traditional diagnostic methods and treatments, such as clinical evaluation and scaling, often fall short in early detection and targeted therapy, particularly in complex or advanced cases. Recent advancements in nanomedicine offer promising solutions for improving both the diagnosis and treatment of periodontitis.
View Article and Find Full Text PDFSynthetic Vesicle-Based Drug Delivery Systems for Oral Disease Therapy: Current Applications and Future Directions.
J Funct Biomater
January 2025
Hospital of Stomatology, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou 510055, China.
Oral diseases such as dental caries, periodontitis, and oral cancer are prevalent and present significant challenges to global public health. Although these diseases are typically treated through procedures like dental preparation and resin filling, scaling and root planning, or surgical excision, these interventions are often not entirely effective, and postoperative drug therapy is usually required. Traditional drug treatments, however, are limited by factors such as poor drug penetration, significant side effects, and the development of drug resistance.
View Article and Find Full Text PDFCyclodextrin-based delivery systems for chemical and genetic drugs: Current status and future.
Carbohydr Polym
March 2025
Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China. Electronic address:
Cyclodextrins (CDs) are cyclic polysaccharides characterized by their unique hollow structure, making them highly effective carriers for pharmaceutical agents. CD-based delivery systems are extensively utilized to enhance drug stability, increase solubility, improve oral bioavailability, and facilitate controlled release and targeted delivery. This review initially provides a concise overview of nano drug delivery systems, followed by a detailed introduction of the structural features and benefits of CDs.
View Article and Find Full Text PDFTofacitinib in focus: Fascinating voyage from conventional formulations to novel delivery systems.
Int J Pharm
January 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India. Electronic address:
Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a primary therapeutic agent for managing autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, dermatitis and ulcerative colitis. By inhibiting the phosphorylation of JAK enzymes, tofacitinib prevents their activation within the JAK-STAT signaling pathway, which is vital for inflammatory responses. However, the tofacitinib delivery presents significant challenges, including pH-dependent solubility, poor permeability and susceptibility to oral degradation.
View Article and Find Full Text PDFB-doped nano-hydroxyapatite facilitates proliferation and differentiation of osteoblasts.
J Orthop Surg Res
January 2025
Xuzhou Medical University Affiliated Stomatology Hospital, Xuzhou, 221002, Jiangsu Province, China.
Purpose: We aimed to explore the mechanism by which Boron-doped nano-hydroxyapatite (B-nHAp) facilitates the proliferation and differentiation of osteoblasts through controlled release of B.
Methods: B-nHAp characterization was accomplished by means of X-ray diffraction, scanning electron microscopy, inductively coupled plasma mass spectrometry, and transmission electron microscopy. Human bone marrow mesenchymal stem cells (hBMSCs) were subjected to flow cytometry, alizarin red S staining, and cell counting kit-8 assay for proliferation and differentiation determination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!